CRTX News and Press, Cortexyme Inc. From 05/12/22

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will participate at The 4 th International Conference on Porphyromonas g...

Cortexyme (NASDAQ:CRTX) has agreed to acquire privately-held biotech company Novosteo. Financial terms of the deal were not disclosed. The transaction, which has been approved by the boards of directors of both companies, is expected to close within the next 30 days. Upon deal closing, Novost...

Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO of combined company Planning corporat...

SAN FRANCISCO, April 26, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Cortexyme, Inc. (NASDAQ: CRTX) investors who suffered significant losses to submit your losses now . The firm is investigating possible securities law violations and certain investors may have valuable claims. ...

SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Cortexyme, Inc. (NASDAQ: CRTX) investors who suffered significant losses to submit your losses now . The firm is investigating possible securities law violations and certain investors may have valuable claims. ...

SAN FRANCISCO, CA / ACCESSWIRE / March 21, 2022 / Hagens Berman urges Cortexyme, Inc. (NASDAQ:CRTX) investors who suffered significant losses to submit your losses now . The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit: ...

Target engagement and biomarker data expands understanding of the role of P. gingivalis and the potential benefit of lysine gingipain inhibition Biomarker data and correlations to clinical outcomes consistent with the gingipain hypothesis Cortexyme, Inc. (Nasdaq: CRT...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Marwan Noel Sabbagh, MD, FAAN, a board-certified neurologist an...

New data expands evidence base of role of P. gingivalis in Alzheimer’s disease Discussion to include new biomarker results and correlations between biomarkers and clinical outcomes Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company ...

First-in-class lysine gingipain inhibitor, atuzaginstat, has the potential to reduce the malignant progression of oral potentially malignant disorders (OPMD) In vitro study results demonstrate that PD-L1 is induced by P. gingivalis and can be blocked by atuzaginstat At...